keyword
MENU ▼
Read by QxMD icon Read
search

Aflibercept

keyword
https://www.readbyqxmd.com/read/28630787/evaluation-of-aflibercept-treatment-responses-in-eyes-with-bevacizumab-ranibizumab-resistant-wet-age-related-macular-degeneration
#1
Tuncay Topal, Taner Kar, Yıldıray Yıldırım, Sercan Koray Sağdıç, Cihan Büyükavşar, Abdullah Kaya, Ali Ayata, Murat Sönmez, Melih Hamdi Ünal
OBJECTIVES: To evaluate anatomic and functional results after switching from intravitreal bevacizumab or ranibizumab treatment to aflibercept for wet (neovascular) age-related macular degeneration. MATERIALS AND METHODS: This retrospective study included 22 eyes of 22 patients resistant to treatment with at least 6 injections of bevacizumab or ranibizumab. The first three injections had been applied monthly, the others pro re nata (PRN). Outcome measures were follow-up period, injection number, best corrected visual acuity (BCVA), central retinal thickness (CRT) and pigment epithelial detachment (PED) height...
June 2017: Turkish Journal of Ophthalmology
https://www.readbyqxmd.com/read/28624325/treat-and-extend-therapy-using-aflibercept-for-neovascular-age-related-macular-degeneration-a-prospective-clinical-trial
#2
Francis Char DeCroos, David Reed, Murtaza K Adam, David Salz, Omesh P Gupta, Allen C Ho, Carl D Regillo
PURPOSE: To determine the efficacy and durability of aflibercept utilized in a treat and extend (TAE) regimen for neovascular age-related macular degeneration (NVAMD). DESIGN: Multicenter, prospective, open label, non-comparative, interventional study METHODS: Forty eyes of 40 patients with treatment-naïve NVAMD were managed with a TAE regimen of intravitreal aflibercept. The main endpoints were the change in mean and median best-corrected visual acuity from baseline at years 1 and 2...
June 14, 2017: American Journal of Ophthalmology
https://www.readbyqxmd.com/read/28622328/second-year-visual-acuity-outcomes-of-namd-patients-treated-with-aflibercept-data-analysis-from-the-uk-aflibercept-users-group
#3
H Almuhtaseb, R L Johnston, J S Talks, A J Lotery
PurposeTo audit the visual acuity (VA) outcomes achieved at the end of year two in 17 UK centres, which followed the year 1 VIEW protocol in year 1, but a variable approach in year 2 for aflibercept for neovascular macular degeneration (nAMD).Patients and methodsRetrospective data analysis, from an electronic medical record, of a consecutive series of treatment-naive nAMD patients who received aflibercept for 2 consecutive years, having followed the VIEW protocol in year one, defined as eyes having received 7 or 8 injections from baseline...
June 16, 2017: Eye
https://www.readbyqxmd.com/read/28622326/clinical-real-world-results-of-switching-treatment-from-ranibizumab-to-aflibercept-in-patients-with-diabetic-macular-oedema
#4
V E Konidaris, K T Tsaousis, Z Al-Hubeshy, K Pieri, J Deane, T Empeslidis
No abstract text is available yet for this article.
June 16, 2017: Eye
https://www.readbyqxmd.com/read/28622036/molecular-targeted-drugs-and-treatment-of-colorectal-cancer-recent-progress-and-future-perspectives
#5
Fang Geng, Zheng Wang, Hang Yin, Junxian Yu, Bangwei Cao
Nowadays, colorectal cancer is the fourth most common type of tumor all over the world. When diagnosed, ∼50%-60% of tumors have metastasized, thus resulting in a grim prognosis. Chemotherapy is regarded as standard treatment for patients with colorectal cancer, however, limitations of chemotherapy cannot be ignored, such as low selectivity, insufficient concentrations in tumor tissues, and systemic toxicity. Recently, six targeted drugs have been approved by the U.S. Food and Drug Administration (FDA) for treatment of metastatic colorectal cancer (mCRC), including bevacizumab, aflibercept, regorafenib, cetuximab, and panitumumab...
June 2017: Cancer Biotherapy & Radiopharmaceuticals
https://www.readbyqxmd.com/read/28621038/aqueous-vascular-endothelial-growth-factor-and-aflibercept-concentrations-after-bimonthly-intravitreal-injections-of-aflibercept-for-age-related-macular-degeneration
#6
Tomoko Sawada, Xiying Wang, Osamu Sawada, Yoshitsugu Saishin, Masahito Ohji
IMPORTANCE: Clinical evidence supports the efficacy of bimonthly injection of aflibercept for age-related macular degeneration. BACKGROUND: To evaluate aqueous vascular endothelial growth factor and aflibercept concentrations and the efficacy of bimonthly aflibercept injections in patients with age-related macular degeneration. DESIGN A PROSPECTIVE, INTERVENTIONAL CASE SERIES: PARTICIPANTS: Thirty-five eyes with exudative age-related macular degeneration...
June 16, 2017: Clinical & Experimental Ophthalmology
https://www.readbyqxmd.com/read/28614154/regression-of-inflamed-pterygia-by-frequent-high-dose-intralesional-ziv-aflibercept
#7
Ahmad M Mansour
PURPOSE: Intralesional single low-dose vascular endothelial growth factor antagonists have traditionally failed in causing regression of pterygia. The current pilot study investigates the role of high-dose repeated intralesional ziv-aflibercept in causing regression of inflamed or recurring pterygia. METHODS: This prospective study from January 2015 to April 2017 consisted of using high dose of ziv-aflibercept between 0.1 mL (2.5 mg) and 0.3 mL (7.5 mg), depending on the pterygium size and the degree of inflammation...
June 13, 2017: Cornea
https://www.readbyqxmd.com/read/28604541/high-dose-high-frequency-aflibercept-for-recalcitrant-neovascular-age-related-macular-degeneration
#8
Qi Sheng You, Raouf Gaber, Amit Meshi, Hema L Ramkumar, Mostafa Alam, Ilkay Kilic Muftuoglu, William R Freeman
PURPOSE: To determine the efficacy of monthly (0.1 mL/4 mg) aflibercept for refractory neovascular age-related macular degeneration (wet age-related macular degeneration). METHODS: This was a retrospective interventional case series in which patients with wet age-related macular degeneration were treated with stepwise dose escalation. Nonvitrectomized patients resistant to monthly (Q4W) ranibizumab/bevacizumab were switched to 2 mg aflibercept every 8 weeks. With resistance, they were escalated to Q4W 2 mg aflibercept, then Q4W 4 mg (high dose high frequency, 4Q4W) aflibercept...
June 9, 2017: Retina
https://www.readbyqxmd.com/read/28601912/effects-of-photodynamic-therapy-plus-intravitreal-aflibercept-with-subtenon-triamcinolone-injections-for-aflibercept-resistant-polypoidal-choroidal-vasculopathy
#9
Tsutomu Sakai, Noriko Kato, Masaomi Kubota, Hiroshi Tsuneoka
PURPOSE: To evaluate the outcome of triple therapy of photodynamic therapy combined with injections of intravitreal aflibercept (IVA) and subtenon triamcinolone acetonide for polypoidal choroidal vasculopathy (PCV) resistant to IVA. METHODS: A retrospective chart review at a single institution was conducted to identify patients with PCV resistant to treatment with IVA who were switched to treatment with triple therapy. In total, 13 eyes from 13 patients were included in the study...
June 11, 2017: Graefe's Archive for Clinical and Experimental Ophthalmology
https://www.readbyqxmd.com/read/28596286/one-year-outcome-of-intravitreal-ziv-aflibercept-therapy-for-non-responsive-neovascular-age-related-macular-degeneration
#10
Imoro Zeba Braimah, Komal Agarwal, Ahmad Mansour, Jay Chhablani
AIM: To evaluate 12-month outcome of intravitreal ziv-aflibercept (IVZ) therapy in eyes with neovascular age-related macular degeneration (nAMD) that are non-responsive to bevacizumab and ranibizumab. METHODS: This retrospective study included 16 eyes (14 patients) with nAMD who were on prior treatment with bevacizumab and ranibizumab and were treated with as-needed IVZ (1.25 mg/0.05 mL) for 12 months. The primary outcome measure was the mean change in best corrected visual acuity (BCVA) and secondary outcome measures included mean change in central macular thickness (CMT), retinal pigment epithelial detachment (RPED) heights, longest treatment free interval, presence of subretinal fluid (SRF) and intraretinal fluid (IRF) and adverse events...
June 8, 2017: British Journal of Ophthalmology
https://www.readbyqxmd.com/read/28590316/recurrence-of-choroidal-neovascularization-lesion-activity-after-aflibercept-treatment-for-age-related-macular-degeneration
#11
Tomotaka Wakazono, Kenji Yamashiro, Akio Oishi, Sotaro Ooto, Hiroshi Tamura, Yumiko Akagi-Kurashige, Masayuki Hata, Ayako Takahashi, Akitaka Tsujikawa, Nagahisa Yoshimura
PURPOSE: To examine the recurrence rate of choroidal neovascularization (CNV) lesion activity in age-related macular degeneration (AMD) and associated factors after 1-year aflibercept treatment. METHODS: Age-related macular degeneration eyes with 1-year aflibercept fixed-regimen treatment and a follow-up period of at least 18 months from the initial aflibercept injection for treatment-naive exudative AMD were retrospectively evaluated. The recurrence rate was examined...
January 11, 2017: Retina
https://www.readbyqxmd.com/read/28576208/long-term-in-vitro-functional-stability-of-compounded-ranibizumab-and-aflibercept
#12
Sijia Cao, Jing Cui, Joanne Matsubara, Farzin Forooghian
OBJECTIVE: To determine the long-term in vitro functional stability of compounded ranibizumab and aflibercept. DESIGN: Laboratory study. METHODS: Ranibizumab and aflibercept were compounded into plastic syringes and stored under refrigerated conditions for up to 4 weeks. Half maximal inhibitory concentrations (IC50) from dose-response curves generated by using drugs and their respective targets in enzyme-linked immunosorbent assays were calculated...
June 2017: Canadian Journal of Ophthalmology. Journal Canadien D'ophtalmologie
https://www.readbyqxmd.com/read/28575913/-results-of-re-switch-from-intravitreal-aflibercept-to-ranibizumab-in-patients-with-exudative-age-related-macular-degeneration
#13
Sören Waibel, Egbert Matthé, Dirk Sandner
Background The purpose of this study was to investigate the effectiveness of re-switch from intravitreal aflibercept to ranibizumab in patients with exudative age-related macular degeneration. Materials and Methods This retrospective case series included 17 eyes of 17 patients who had previously switched from ranibizumab to aflibercept and finally back to ranibizumab. Main outcomes were change of visual acuity (VA) and assessment of central macular thickness (CMT). Secondary outcomes included predictive factors which had a beneficial effect as VA and CMT before re-switch, number of previous injections and gender...
June 2, 2017: Klinische Monatsblätter Für Augenheilkunde
https://www.readbyqxmd.com/read/28570735/accuracy-of-billing-codes-used-in-the-therapeutic-care-of-diabetic-retinopathy
#14
Marisa Lau, Jonathan L Prenner, Alexander J Brucker, Brian L VanderBeek
Importance: Insurance billing claim databases represent a growing field of scientific inquiry within ophthalmology. Validating the accuracy of billing claim codes used during the care of diabetic retinopathy is a necessary precursor to fully understanding the underlying data and subsequent results of these types of studies. Objective: To determine the accuracy of diagnostic, procedural, and therapeutic billing codes used in the treatment of diabetic retinopathy...
June 1, 2017: JAMA Ophthalmology
https://www.readbyqxmd.com/read/28570733/results-of-a-randomized-clinical-trial-of-aflibercept-vs-panretinal-photocoagulation-for-proliferative-diabetic-retinopathy-is-it-time-to-retire-your-laser
#15
https://www.readbyqxmd.com/read/28559722/topical-versus-subconjunctival-anti-vascular-endothelial-growth-factor-therapy-bevacizumab-ranibizumab-and-aflibercept-for-treatment-of-corneal-neovascularization
#16
REVIEW
Tariq Al-Debasi, Abdulkareem Al-Bekairy, Abdulmalik Al-Katheri, Shmeylan Al Harbi, Mahmoud Mansour
In order to evaluate the effect of topical and subconjunctival anti-vascular endothelial growth factor (anti-VEGF) therapy, Ranibizumab, Bevacizumab and Aflibercept as a therapy for corneal neovascularization (NV) treatment, the aim of this study was to review all data related to some of anti-VEGF as a promising therapies for corneal NV treatment. Corneal NV is a dangerous condition leading to a marked reduction in vision due to angiogenesis of abnormal vessels that block light. During the recent years, we have recognized new drug proliferation for corneal NV treatment...
April 2017: Saudi Journal of Ophthalmology: Official Journal of the Saudi Ophthalmological Society
https://www.readbyqxmd.com/read/28558181/an-update-on-intravitreal-aflibercept-in-treating-macular-diseases
#17
EDITORIAL
Timothy Y Y Lai
No abstract text is available yet for this article.
May 2017: Asia-Pacific Journal of Ophthalmology
https://www.readbyqxmd.com/read/28557667/real-life-experience-with-aflibercept-and-ranibizumab-in-the-treatment-of-newly-diagnosed-neovascular-age-related-macular-degeneration-over-24-months
#18
Justus G Garweg, Christin Gerhardt, Laurent Kodjikian, Isabel B Pfister
PURPOSE: Comparative data appertaining to the long-term effects of Aflibercept or Ranibizumab in newly diagnosed cases of neovascular age-related macular degeneration (nAMD) over follow-up periods exceeding 12 months in clinical routine are scarce. METHODS: In this retrospective comparative analysis, a case series of patients with treatment-naïve nAMD and requiring anti-vascular endothelial growth factor (VEGF) therapy in a routine clinical setting were treated with either Aflibercept [Afl (n = 106)] or Ranibizumab [Ran (n = 47)]...
May 30, 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28557571/in-vivo-efficacy-of-an-injectable-microsphere-hydrogel-ocular-drug-delivery-system
#19
Christian R Osswald, Micah J Guthrie, Abigail Avila, Joseph A Valio, William F Mieler, Jennifer J Kang-Mieler
PURPOSE: Demonstrate in vivo that controlled and extended release of a low dose of anti-vascular endothelial growth factor (anti-VEGF) from a microsphere-hydrogel drug delivery system (DDS) has a therapeutic effect in a laser-induced rat model of choroidal neovascularization (CNV). METHODS: Anti-VEGF (ranibizumab or aflibercept) was loaded into poly(lactic-co-glycolic acid) microspheres that were then suspended within an injectable poly(N-isopropylacrylamide)-based thermo-responsive hydrogel DDS...
May 30, 2017: Current Eye Research
https://www.readbyqxmd.com/read/28556485/two-year-functional-and-anatomical-results-after-converting-treatment-resistant-eyes-with-exudative-age-related-macular-degeneration-to-aflibercept-in-accordance-with-a-treat-and-extend-protocol
#20
Øystein Kalsnes Jørstad, Rowan Thomas Faber, Morten Carstens Moe
PURPOSE: To study the effects of converting to aflibercept in accordance with a treat and extend (T&E) strategy in eyes with treatment resistant exudative age-related macular degeneration (AMD). METHODS: Two-year prospective study of eyes with exudative AMD and persistent macular fluid despite monthly treatment with ranibizumab or bevacizumab. Eyes were converted to 2.0 mg aflibercept in accordance with a T&E protocol. RESULTS: Fifty eyes from 47 patients were included...
May 29, 2017: Acta Ophthalmologica
keyword
keyword
1772
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"